Heparin-induced thrombocytopenia: Current status and diagnostic challenges

American Journal of Hematology

Volumn 85, Issue 9, 2010, Pages 700-706

  Otis, Stavroula A ^a   Zehnder, James L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; ANTIBODY; ANTICOAGULANT AGENT;

ANTIBODY DETECTION; ANTICOAGULATION; BLEEDING; CLINICAL ASSESSMENT; CLINICAL FEATURE; DELAYED DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOASSAY; LABORATORY DIAGNOSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STANDARDIZATION; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; THROMBOCYTE; THROMBOCYTOPENIA;

ANTIBODIES; ANTICOAGULANTS; BLOOD PLATELETS; HEMORRHAGE; HEPARIN; HUMANS; IMMUNOASSAY; PLATELET ACTIVATION; RISK FACTORS; THROMBOCYTOPENIA;

EID: 77956495415     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21770     Document Type: Review

References (54)

1. Greinacher A, Potzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71:247-251.
2. Amiral J. Platelet factor 4, target of anti-heparin antibodies: application to biological diagnosis of heparin-induced thrombopenia. Ann Med Int (Paris) 1997;148:142-149.
3. Rauova L, Poncz M, McKenzie SE, et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005;105:131-138.
4. Rauova L, Zhai L, Kowalska MA, et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: Diagnostic and therapeutic implications. Blood 2006;107:2346-2353.
5. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992;68:95-96.
6. Kelton JG, Smith JW, Warkentin TE, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994;83:3232-3239.
7. Visentin GP, Ford SE, Scott JP, et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994;93:81-88.
8. Chong BH, Fawaz I, Chesterman CN, et al. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989;73:235-240.
9. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005;127:35S-45S.
10. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000;96:182-187.
11. Tardy-Poncet B, Piot M, Chapelle C, et al. Thrombin generation and heparin-induced thrombocytopenia. J Thromb Haemost 2009;7:1474-1481.
12. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-1292.
13. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133: 340S-380S.
14. Greinacher A, Kohlmann T, Strobel U, et al. The temporal profile of the anti-PF4/heparin immune response. Blood 2009;113:4970-4976.
15. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759-765.
16. Pouplard C, Gueret P, Fouassier M, et al. Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2007;5:1373-1379.
17. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121:535-555.
18. Arepally G, Reynolds C, Tomaski A, et al. Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995;104:648-654.
19. Greinacher A, Michels I, Kiefel V, et al. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991;66:734-736.
20. Eichler P, Raschke R, Lubenow N, et al. The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br J Haematol 2002;116:887-891.
21. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27-30.
22. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993;69:344-350.
23. Price EA, Hayward CP, Moffat KA, et al. Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: A survey of North American specialized coagulation laboratories. Thromb Haemost 2007;98: 1357-1361.
24. Pouplard C, Amiral J, Borg JY, et al. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999;111:700-706.
25. Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia: A prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007;5:1666-1673.
26. Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-1708.
27. Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997;95:1242-1246.
28. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest 2007;131:1644-1649.
29. Trossaert M, Gaillard A, Commin PL, et al. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998;101:653-655.
30. Francis JL, Palmer GJ, III, Moroose R, et al. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 2003;75:17-22.
31. Zwicker JI, Uhl L, Huang WY, et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004;2:2133-2137.
32. Lindhoff-Last E, Gerdsen F, Ackermann H, et al. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2001;113:886-890.
33. Suh JS, Malik MI, Aster RH, et al. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol 1997;54:196-201.
34. Alberio L, Kimmerle S, Baumann A, et al. Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am J Med 2003;114:528-536.
35. Warkentin TE, Sheppard JI, Moore JC, et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008;6:1304-1312.
36. Pauzner R, Greinacher A, Selleng K, et al. False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost 2009;7:1070-1074.
37. Whitlatch NL, Perry SL, Ortel TL. Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 2008;100:678-684.
38. Warkentin TE, Sheppard JI, Moore JC, et al. The use of well-characterized sera for the assessment of new diagnostic enzyme-immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2010;8:216-218.
39. Amiral J. Antigens involved in heparin-induced thrombocytopenia. Semin Hematol 1999;36:7-11.
40. Amiral J, Marfaing-Koka A, Wolf M, et al. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996;88:410-416.
41. Untch B, Ahmad S, Jeske WP, et al. Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG. Thromb Res 2002;105:117-123.
42. Bakchoul T, Giptner A, Najaoui A, et al. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2009;7:1260-1265.
43. Meyer O, Salama A, Pittet N, et al. Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4). Lancet 1999;354: 1525-1526. (Pubitemid 29502110)
44. Schneiter S, Colucci G, Sulzer I, et al. Variability of anti-PF4/heparin antibody results obtained by the rapid testing system ID-H/PF4-PaGIA. J Thromb Haemost 2009;7:1649-1655.
45. Tazzari PL, Ricci F, Vitale M, et al. Heparin-induced thrombocytopenia: Detection of antiheparin/PF4 antibodies by means of heparin/PF4-coated beads and flow cytometry. Transfus Med 2002;12:193-198.
46. Gobbi G, Mirandola P, Tazzari PL, et al. New laboratory test in flow cytometry for the combined analysis of serologic and cellular parameters in the diagnosis of heparin-induced thrombocytopenia. Cytometry B Clin Cytom 2004;58:32-38.
47. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 1998;80:292-297.
48. Walenga JM, Jeske WP, Fasanella AR, et al. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost 1999;25(Suppl 1):43-49.
49. Michelson AD, Barnard MR, Krueger LA, et al. Evaluation of platelet function by flow cytometry. Methods 2000;21:259-270.
50. Lee DH, Warkentin TE, Denomme GA, et al. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br J Haematol 1996;95:724-731.
51. Warkentin TE, Sheppard JA, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006;108:2937-2941.
52. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335.
53. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-PF4/heparin antibody formation post-orthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. J Thromb Haemost 2010;8:504-512.
54. Warkentin TE, Sheppard JA. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev 2006;20:259-272.